Status:
COMPLETED
ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage II to IIIA NSCLC by NGS
Lead Sponsor:
Sun Yat-sen University
Conditions:
NSCLC
Eligibility:
All Genders
18-75 years
Brief Summary
The second generation of high-throughput gene sequencing (NGS) is an important means of detecting the tumor DNA and circulating tumor DNA (ctDNA), which can detect trace ctDNA from smaller plasma samp...
Detailed Description
In the NGS era, ctDNA detection can truly reflect the real tumor tissue gene mutation map and frequency. It becomes the evaluation of therapeutic effect and the important monitoring indicators of clin...
Eligibility Criteria
Inclusion
- Postoperative histopathological diagnosis of TNM stage IIA to IIIA NSCLC with R0 resection;
- No previous chemotherapy, radiotherapy, surgery or biological therapy for lung cancer；
- Eastern Cooperative Oncology Group (ECOG) behavior status score 0 to 1.
Exclusion
- Patients with other cancers other than NSCLC within five years prior to this study;
- Who can not get enough tumor histological specimens (non-cytological) for analysis;
- Human immunodeficiency virus (HIV) infection;
- NSCLC mixed with patients with small cell lung cancer;
- Pregnant or lactating women;
- There is a clear history of neurological or mental disorders, including epilepsy or dementia;
- Conditions that investigators think is not suitable for inclusion.
Key Trial Info
Start Date :
October 21 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2021
Estimated Enrollment :
119 Patients enrolled
Trial Details
Trial ID
NCT03465241
Start Date
October 21 2017
End Date
February 1 2021
Last Update
July 30 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China